This spring LexaGene conducted a market research survey in conjunction with AAHA to assess the opinions of practicing veterinarians on AMR stewardship and the use of antibiotics in the treatment of companion animals.
The most menacing of all resistant bacteria are the so called “super bugs”- strains of bacteria that are resistant to several different classes of antibiotics or multidrug resistant.
Rapid advancements in PCR testing can replace existing culture & sensitivity testing, providing faster results, preventing unnecessary antibiotic overuse, promoting AMR stewardship.
Physicians and veterinarians can now confidently detect resistance markers and make evidence-based treatment decisions early in an infection to improve patient outcomes.
Three days is a long time to wait when your pet is feeling ill to secure an appointment and then wait even more days for laboratory blood results from the reference lab.
Learn more about new FDA antimicrobial stewardship guidance impacts the world of veterinary medicine in the coming years and how LexaGene’s MiQLab™ offers a solution.
Learn more about the MiQLab solution offering in-clinic point-of-care veterinary diagnostic testing in ~2 hours addressing more than 50 percent of companion animal vet visits and increasing satisfaction.
LexaGene’s MiQLab has direct benefits for veterinary clinics. Using LexaGene’s proven point-of-care diagnostics for evidence-based treatment of common bacterial infections found in companion animals may also result in cost savings.
When thinking about how best to isolate a bacterium, scientists were often held to the standards of taking time to grow cultures in laboratories, a process involving days or weeks to simply prepare the sample for testing.
We share a lot with our pets, like the bonds of family and multi-drug resistant bacteria.
More than ever, vet practices are looking for efficient and cost-effective methodologies to take control of these variables and manage costs.
The global bioburden testing market for bio-pharma contamination is approximately $10B, with over 350M tests run annually. LexaGene provides early detection for mycoplasma, aiding in validating product quality for biopharmaceutical manufacturers.